Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE

By sjmartinez • May 29, 2023

Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE. Br J Haematol. 2023 May 29. doi: 10.1111/bjh.18883. Epub ahead of print. PMID: 37246588.

Tags: chronic phase chronic myeloid leukaemia, dasatinib, deep molecular response, Hematology/Oncology, major molecular response, Publications, treatment-free remission

Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study

Yamamoto K, Bando H, Misumi T, Nishikawa T, Wakabayashi M, Yamazaki K, Maehara Y, Oki E, Saltz LB, Douillard JY, Punt CJ, Koopman M, Van[...]

Transient rapamycin treatment avoids unwanted host immune responses toward AAV-delivered anti-HIV antibodies

Fuchs SP, Mondragon PG, Zabizhin R, Tomer S, Wang L, Cook E, Dudley DM, Weisgrau KL, Furlott J, Coonen J, Alexander E, Xie J, Gao[...]

Lower dose and weekly schedules of selinexor in multiple myeloma – updated evidence on safety and efficacy

Baljevic M, Schiller G, Mark TM, Van Domelen DR, Gasparetto C. Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on[...]